Nature Reviews Disease Primers, 2021 Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common type of liver cancer after hepatocellular carcinoma, accounting for 10-15% of all primary liver malignancies. Both the incidence and mortality of CCA have been steadily increasing during the last decade.
Paul J Brindley +2 more
exaly +8 more sources
Lancet, The, 2014 Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal).
Nataliya Razumilava, Gregory J Gores
exaly +4 more sources
Modulation of STAT3 signaling, cell redox defenses and cell cycle checkpoints by β-caryophyllene in cholangiocarcinoma cells: possible mechanisms accounting for doxorubicin chemosensitization and chemoprevention [PDF]
, 2020 Cholangiocarcinoma (CCA) is an aggressive group of biliary tract cancers, characterized by late diagnosis, low effective chemotherapies, multidrug resistance, and poor outcomes.
Di Giacomo, Silvia +8 more
core +1 more source
Updated management of malignant biliary tract tumors: an illustrative review [PDF]
, 2016 The management of malignant biliary tumors (MBTs) is complex and requires a multidisciplinary approach. Guidelines and methods of staging for biliary tumors have recently been released by main international societies, altering the clinical and radiologic
Cannavale, Alessandro +6 more
core +1 more source
A case of distal extrahepatic cholangiocarcinoma with two positive resection margins [PDF]
, 2016 Cholangiocarcinoma is an uncommon primary malignancy of the biliary tract that is challenging to diagnose and treat effectively due to its relatively silent and late clinical presentation.
Andersen +42 more
core +2 more sources
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation [PDF]
, 1998 Background: Because of the rarity of hilar cholangiocarcinoma, its prognostic risk factors have not been sufficiently analyzed. This retrospective study was undertaken to evaluate various pathologic risk factors which influenced survival after curative ...
Dvorchik, I +7 more
core +1 more source
Serum micrornas as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma [PDF]
, 2016 The diagnosis of primary sclerosing cholangitis (PSC) is difficult due to the lack of sensitive and specific biomarkers, as is the early diagnosis of cholangiocarcinoma (CC), a complication of PSC.
Alpini, Gianfranco +17 more
core +2 more sources
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. [PDF]
, 2013 PurposePatients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease. methods: Given the overall poor prognosis in this population and the availability of novel targeted therapies, we ...
Falchook, Gerald S +14 more
core +2 more sources
Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas [PDF]
, 2019 The bile duct system and pancreas show many similarities due to their anatomical proximity and common embryological origin. Consequently, preneoplastic and neoplastic lesions of the bile duct and pancreas share analogies in terms of molecular ...
Alvaro, D +10 more
core +1 more source
Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholagnitis [PDF]
, 2018 The non-invasive differentiation of malignant and benign biliary disease is a clinical challenge. Carbohydrate antigen 19-9 (CA19-9), leucine-rich α2-glycoprotein (LRG1), interleukin 6 (IL6), pyruvate kinase M2 (PKM2), cytokeratin 19 fragment (CYFRA21.1)
Blyuss, O +9 more
core +2 more sources